|
|
|||||||||||||
|
ADAR enzymes drive RNA editing by converting adenosine to inosine, which influences RNA stability, splicing, and translation. ADAR-based therapies are emerging as a precise approach in RNA editing, offering higher specificity compared to DNA editing methods like CRISPR-Cas9. Engineered ADAR systems, in combination with guide RNAs (gRNAs), enable site-specific RNA editing to cure genetic diseases. SignalChem Biotech is proud to introduce its new recombinant human ADAR proteins: ADAR1 (p150), ADAR1 (p110), and ADAR2L (ADARB1). These tools support research into ADAR’s functions and therapeutic strategies, including in vitro deamination assays to study RNA editing mechanisms, identify RNA targets, and screen potential modulators. |
|||||||||||||
|
ADAR enzyme-driven A-to-I editing |
|||||||||||||
|
Featured ADAR Products |
|||||||||||||
|
Don’t Miss Out! |
|||||||||||||
|
|||||||||||||
|
|||||||||||||
 |
SinoBiological | 利用我們最新開發的人類重組蛋白 ADAR 進行標靶 RNA 編輯
2025.01.03
